Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
C Aschele, D Debernardis, R Bandelloni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
S Cascinu, M P Staccioli, G Gasparini, et al.
British Journal of Cancer
|
December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
S Cascinu, R Berardi, S Salvagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, R Labianca, V Catalano, et al.
Oncoimmunology
|
November 11, 2017
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
S Meraviglia, E Lo Presti, M Tosolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
S Cascinu, R R Silva, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
S Cascinu, V Catalano, C Aschele, et al.
British Journal of Cancer
|
June 27, 2002
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
F Graziano, R Bisonni, V Catalano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2008
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus, Kevin Imrie, Philippe Solal-Celigny, et al.
British Journal of Cancer
|
April 15, 2004
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, M Scartozzi, R Labianca, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2002
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
C Aschele, D Debernardis, R Bandelloni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
S Cascinu, M P Staccioli, G Gasparini, et al.
British Journal of Cancer
|
December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
S Cascinu, R Berardi, S Salvagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, R Labianca, V Catalano, et al.
Oncoimmunology
|
November 11, 2017
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
S Meraviglia, E Lo Presti, M Tosolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 6, 1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
S Cascinu, R R Silva, R Labianca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
S Cascinu, V Catalano, C Aschele, et al.
British Journal of Cancer
|
June 27, 2002
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
F Graziano, R Bisonni, V Catalano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2008
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus, Kevin Imrie, Philippe Solal-Celigny, et al.
British Journal of Cancer
|
April 15, 2004
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
S Cascinu, M Scartozzi, R Labianca, et al.
Page
of 9